Squamous Cell Carcinoma of Unknown Primary: Clinical Trials

3 trials for Squamous Cell Carcinoma of Unknown Primary, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 1 completed. 3 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 23Active not recruiting 2, Completed 1
Phase 31Completed 1

Follow Squamous Cell Carcinoma of Unknown Primary: new trials by email Literature Review of Squamous Cell Carcinoma of Unknown Primary trials Research Report on Squamous Cell Carcinoma of Unknown Primary

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Carboplatin, Cemiplimab, Paclitaxel - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma
Phase 2Active not recruitingMarcelo Bonomi462021-11-302026-06-25
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Cetuximab, Durvalumab, Intensity-Modulated Radiation Therapy - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma
Phase 2 / Phase 3CompletedNational Cancer Institute (NCI)1962018-04-032026-08-27
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive
Phase 2Active not recruitingNational Cancer Institute (NCI)682017-09-272026-11-12

Narrower conditions

Hypopharyngeal Neoplasms (2)  ·  Laryngeal Neoplasms (2)  ·  Mouth Neoplasms (2)  ·  Oropharyngeal Neoplasms (2)  ·  Squamous Cell Carcinoma of Head and Neck (2)  ·  Adenocarcinoma, Papillary (1)  ·  Carcinoma (1)  ·  Carcinoma, Basal Cell (1)  ·  Carcinoma, Basosquamous (1)  ·  Carcinoma, Merkel Cell (1)  ·  Carcinoma, Signet Ring Cell (1)  ·  Eccrine Porocarcinoma (1)  ·  Lymphoma, Large-Cell, Anaplastic (1)  ·  Lymphoma, T-Cell (1)  ·  Lymphoma, T-Cell, Cutaneous (1)

Broader conditions

Neoplasms (3)  ·  Neoplasms by Histologic Type (3)  ·  Neoplasms by Site (3)  ·  Neoplasms, Glandular and Epithelial (3)  ·  Carcinoma (2)  ·  Carcinoma, Squamous Cell (2)  ·  Head and Neck Neoplasms (2)  ·  Laryngeal Diseases (2)  ·  Mouth Diseases (2)  ·  Otorhinolaryngologic Diseases (2)  ·  Otorhinolaryngologic Neoplasms (2)  ·  Pharyngeal Diseases (2)  ·  Pharyngeal Neoplasms (2)  ·  Respiratory Tract Diseases (2)  ·  Respiratory Tract Neoplasms (2)

Interventions

(225)Ac-DOTA-c(RGDyK) (1)  ·  Biopsy (1)  ·  Carboplatin (1)  ·  Cetuximab (1)  ·  Disulfides (1)  ·  Immunoglobulin G (1)  ·  Nivolumab (1)  ·  Paclitaxel (1)  ·  Radiotherapy, Intensity-Modulated (1)  ·  Specimen Handling (1)  ·  Taxes (1)  ·  cemiplimab (1)  ·  durvalumab (1)  ·  talimogene laherparepvec (1)

Sponsors

National Cancer Institute (NCI) (2)  ·  Marcelo Bonomi (1)

Countries

United States (3)  ·  Canada (1)

Top investigators

Loren K Mell (1)  ·  Marcelo R Bonomi, MD (1)

Results publications

PMID 38664936, PMID 39551064

NIH funding

U10CA180868 (1), UM1CA186709 (1), UM1CA186716 (1)